These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27609465)

  • 1. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.
    Yang C; Zhou Q; Li M; Tong X; Sun J; Qing Y; Sun L; Yang X; Hu X; Jiang J; Yan X; He L; Wan C
    Sci Rep; 2016 Sep; 6():33078. PubMed ID: 27609465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
    Chiu SJ; Lee YJ; Hsu TS; Chen WS
    Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1.
    Rattanawong A; Payon V; Limpanasittikul W; Boonkrai C; Mutirangura A; Wonganan P
    Oncol Rep; 2018 Jan; 39(1):227-238. PubMed ID: 29138869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells.
    Hata T; Yamamoto H; Ngan CY; Koi M; Takagi A; Damdinsuren B; Yasui M; Fujie Y; Matsuzaki T; Hemmi H; Xu X; Kitani K; Seki Y; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Mol Cancer Ther; 2005 Oct; 4(10):1585-94. PubMed ID: 16227409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
    Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
    BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines.
    Howells LM; Mitra A; Manson MM
    Int J Cancer; 2007 Jul; 121(1):175-83. PubMed ID: 17330230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
    Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
    Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
    Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
    Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
    Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
    Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2S1 depletion enhances colorectal cell proliferation is associated with PGE2-mediated activation of β-catenin signaling.
    Yang C; Li C; Li M; Tong X; Hu X; Yang X; Yan X; He L; Wan C
    Exp Cell Res; 2015 Feb; 331(2):377-86. PubMed ID: 25557876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.
    Kiyonari S; Iimori M; Matsuoka K; Watanabe S; Morikawa-Ichinose T; Miura D; Niimi S; Saeki H; Tokunaga E; Oki E; Morita M; Kadomatsu K; Maehara Y; Kitao H
    Mol Cancer Ther; 2015 Oct; 14(10):2332-42. PubMed ID: 26208523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
    Jang CH; Moon N; Oh J; Kim JS
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor functions of miR-133a in colorectal cancer.
    Dong Y; Zhao J; Wu CW; Zhang L; Liu X; Kang W; Leung WW; Zhang N; Chan FK; Sung JJ; Ng SS; Yu J
    Mol Cancer Res; 2013 Sep; 11(9):1051-60. PubMed ID: 23723074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells].
    Hou Q; Zhao H; Gong W; Zhu Z; Han Y; Chen D; Guo H
    Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):418-23. PubMed ID: 25241782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.